The fate of N1′-methanesulphonyl-N4′-(9-acridinyl) -3′ -methoxy-2′,5′ -cyclohexadiene-1′,4′-diimine (m-aqdi), the primary oxidative metabolite of amsacrine, in transformed chinese hamster fibroblasts☆

Add time:09/03/2019    Source:sciencedirect.com

The cytotoxicity of the anti-leukaemia drug amsacrine (m-AMSA) has been suggested to result from its oxidative metabolism to the corresponding quinonediimine, N1′-methanesulphonyl-N4′-(9-acridinyl)-3′-methoxy-2′, 5′-cyclohexadiene- 1′.4′-diimine (mAQDI). The metabolic fate of mAQDI was examined in cultured CHO cells (subline AA8) to identify the end products to be expected following oxidative metabolism of m-AMSA. [Acridinyl-G-3H]-m-AQDI was rapidly accumulated by AA8 cells in phosphate buffered saline with complete conversion in less than one minute to m-AMSA, macro-molecular adducts and polar low molecular weight species, each of these three classes being formed in approximately equal amounts. Two of the polar products were chromatographically identical to those formed on reaction of m-AQDI with reduced glutathione. These were identified by 1H NMR spectroscopy as the 1,4-addition product 5′-(S-glutathionyl)-m-AMSA and the previously unreported isomeric 6′-(S-glutathionyl)-m-AMSA. These thiol adducts were also formed rapidly from m-AQDI in deproteinized cell lysates indicating a non-enzymatic process, although the possibility of enzymatic catalysis in intact cells has not been eliminated. The absence of such products in AA8 cells after treatment with m-AMSA places an upper limit of 1% per hour on the rate of its oxidative metabolism in these cells and suggests that generation of m-AQDI is unlikely to be responsible for the cytotoxicity of m-AMSA in cultured tumour cells.

We also recommend Trading Suppliers and Manufacturers of 2-(9-ACRIDINYL)-1-PHENYLETHANONE (cas 15539-52-3). Pls Click Website Link as below: cas 15539-52-3 suppliers

Prev:A reassessment of the mechanism of action of 4′-[(9-acridinyl)-amino]methanesulphon-m-anisidide☆
Next:Review articlePreparation and biodistribution of 1-((2-methoxyphenyl) piperazine)ferrocenecarboxamide labeled with technetium-99m as a potential brain receptor imaging agent)